Oneness Biotech Co., Ltd. (TPEX:4743)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.60
-1.30 (-2.46%)
May 8, 2026, 1:30 PM CST
Market Cap24.73B -10.2%
Revenue (ttm)129.12M +9.5%
Net Income-1.04B
EPS-2.18
Shares Out479.21M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,109,597
Average Volume2,234,176
Open53.30
Previous Close52.90
Day's Range51.50 - 53.70
52-Week Range49.70 - 82.70
Beta0.79
RSI44.23
Earnings DateMay 13, 2026

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, a wound care medical device. The company develops ON101, has completed clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II a clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has received US FDA Phase II clinical trial for the treatment of rheumatoid arthritis and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 4743
Full Company Profile

Financial Performance

In 2025, Oneness Biotech's revenue was 129.12 million, an increase of 9.49% compared to the previous year's 117.93 million. Losses were -1.04 billion, -10.33% less than in 2024.

Financial Statements